Day: February 13, 2021

BROOKFIELD, NEWS, Feb. 13, 2021 (GLOBE NEWSWIRE) — Brookfield Infrastructure Corporation (NYSE: BIPC; TSX: BIPC) today announced that it has filed its 2020 annual report on Form 20-F (the “Annual Report”), including its audited financial statements for the year ended December 31, 2020, with the SEC on EDGAR as well as with the Canadian securities authorities on SEDAR. These documents are also available under the Financial Reports section of our website (bip.brookfield.com/bipc) and a hard copy will be provided to shareholders free of charge upon request.Brookfield Infrastructure is a leading global infrastructure company that owns and operates high-quality, long-life assets in the utilities, transport, midstream and data sectors across North and South America, Asia Pacific and Europe. We are focused on assets that generate stable...

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Roth Capital Partners is acting as the sole placement agent for the offering.Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.A shelf registration statement on Form S-3 (Registration No. 333-231537)...

Steve Muehler, the Founder & Senior Managing Member of Private Placement Markets, today announced that the last piece of the Firm’s year long products & services expansion will open in July of this year, and that is the “Private Paralegal Services Division” of the Private Placement Market. Mr. Steve Muehler will head the Firm’s Paralegal Services division when it opens. The Private Placement Markets – Paralegal Services division will be a non-attorney legal professional services firm that will provide different types of Legal Document Services to Individuals and Companies throughout the State of California for a fee without being under the supervision of a Licensed Attorney. Since the Firm will not be working directly under an attorney, there will be strict limitations as to the services and products provided, and the services...

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) — The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (“Flowr” or the “Company”) announces the granting of incentive stock options to purchase 6,496,000 common shares in the capital of the Company (the “Options”) and 2,970,000 restricted share units (the “RSUs”) to certain employees, officers and directors of the Company, subject to regulatory approval.  The Options and RSUs were granted on February 8, 2021 pursuant to the Company’s applicable incentive plans. The Options are exercisable at a price of $0.44 per share and are set to expire on February 12, 2026.  The Options and RSUs vest as follow: (a) one-third on the first anniversary of when the Options and RSUs were granted; (b) one-third on the second anniversary of when the Options and RSUs were granted; and (c) the remaining one-third on...

– COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy –– Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, and impacted anemia and the need for rescue interventions such as growth factors and red blood cell transfusions –– G1 will host conference call Tuesday, February 16, 2021 at 8:00 a.m. ET –RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved COSELA™ (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression...

VANCOUVER, British Columbia, Feb. 12, 2021 (GLOBE NEWSWIRE) — Cassius Ventures Ltd. (NEX: CZ.H) (the “Company”) announces that the board of directors of the Company has approved the granting, of 250,000 incentive stock options pursuant to the Company’s Stock Option Plan to a director and officer of the Company. The options are exercisable at a price of $0.07 per share. The options expire on February 12, 2026 with 25% of the options granted vesting each quarter over the next four (4) quarters.CASSIUS VENTURES LTD. On behalf of the Board of DirectorsJohn A. Thomas P. EngChairman, CEO and President+1 604 558 1107Neither the NEX nor its Regulation Services Provider (as that term is defined in the policies of the NEX) accepts responsibility for the adequacy or accuracy of this release.